BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol Rev 2019;13:410. [PMID: 31044028 DOI: 10.4081/oncol.2019.410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Mogal MR, Junayed A, Mahmod MR, Sompa SA, Lima SA, Kar N, Tasminatarin, Khatun M, Zubair MA, Sikder MA, Moloney GM. A Computational Approach to Justifying Stratifin as a Candidate Diagnostic and Prognostic Biomarker for Pancreatic Cancer. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/1617989] [Reference Citation Analysis]
2 Chiang CC, Yeh CT, Hwang TL, Chu YD, Lim SN, Chen CW, Kuo CJ, Le PH, Chen TH, Lin WR. The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma. J Clin Med 2019;8:E2225. [PMID: 31888240 DOI: 10.3390/jcm8122225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Sohrabi E, Rezaie E, Heiat M, Sefidi-Heris Y. An Integrated Data Analysis of mRNA, miRNA and Signaling Pathways in Pancreatic Cancer. Biochem Genet 2021. [PMID: 33813720 DOI: 10.1007/s10528-021-10062-x] [Reference Citation Analysis]
4 Wiest NE, Moktan VP, Oman SP, Chirilă RM. Screening for pancreatic cancer: a review for general clinicians. Rom J Intern Med 2020;58:119-28. [PMID: 32364522 DOI: 10.2478/rjim-2020-0009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 DeLouize AM, Eick G, Karam SD, Snodgrass JJ. Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and population-based research. Am J Hum Biol 2021;:e23665. [PMID: 34374148 DOI: 10.1002/ajhb.23665] [Reference Citation Analysis]
6 Pen SL, Shan YS, Hsiao CF, Liu TW, Chen JS, Ho CL, Chou WC, Hsieh RK, Chen LT, Ch'ang HJ. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial. Radiother Oncol 2021;158:146-54. [PMID: 33667587 DOI: 10.1016/j.radonc.2021.02.037] [Reference Citation Analysis]
7 Pan CH, Otsuka Y, Sridharan B, Woo M, Leiton CV, Babu S, Torrente Gonçalves M, Kawalerski RR, K Bai JD, Chang DK, Biankin AV, Scampavia L, Spicer T, Escobar-Hoyos LF, Shroyer KR. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Mol Oncol 2020;14:1800-16. [PMID: 32533886 DOI: 10.1002/1878-0261.12743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Gudagunti FD, Gundlakunta SG, Lima IT. Dielectrophoresis-Based Biosensor for Detection of the Cancer Biomarkers CEA and CA 242 in Serum. Chemosensors 2022;10:104. [DOI: 10.3390/chemosensors10030104] [Reference Citation Analysis]
9 Verloy R, Privat-Maldonado A, Smits E, Bogaerts A. Cold Atmospheric Plasma Treatment for Pancreatic Cancer-The Importance of Pancreatic Stellate Cells. Cancers (Basel) 2020;12:E2782. [PMID: 32998311 DOI: 10.3390/cancers12102782] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Polani F, Grierson PM, Lim KH. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. World J Gastroenterol 2021; 27(18): 2105-2121 [PMID: 34025067 DOI: 10.3748/wjg.v27.i18.2105] [Reference Citation Analysis]
11 Dorrell R, Pawa S, Zhou Y, Lalwani N, Pawa R. The Diagnostic Dilemma of Malignant Biliary Strictures. Diagnostics (Basel) 2020;10:E337. [PMID: 32466095 DOI: 10.3390/diagnostics10050337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein H, Hegel JK, Sharma A, Madin K, Rolny V, Lisy M, Piratvisuth T. Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open. [DOI: 10.1002/jgh3.12720] [Reference Citation Analysis]
13 Pappalardo A, Giunta EF, Tirino G, Pompella L, Federico P, Daniele B, De Vita F, Petrillo A. Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Front Oncol 2021;11:695627. [PMID: 34485130 DOI: 10.3389/fonc.2021.695627] [Reference Citation Analysis]
14 Kartal E, Schmidt TSB, Molina-Montes E, Rodríguez-Perales S, Wirbel J, Maistrenko OM, Akanni WA, Alashkar Alhamwe B, Alves RJ, Carrato A, Erasmus HP, Estudillo L, Finkelmeier F, Fullam A, Glazek AM, Gómez-Rubio P, Hercog R, Jung F, Kandels S, Kersting S, Langheinrich M, Márquez M, Molero X, Orakov A, Van Rossum T, Torres-Ruiz R, Telzerow A, Zych K, Benes V, Zeller G, Trebicka J, Real FX, Malats N, Bork P; MAGIC Study investigators., PanGenEU Study investigators. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 2022:gutjnl-2021-324755. [PMID: 35260444 DOI: 10.1136/gutjnl-2021-324755] [Reference Citation Analysis]
15 Chen S, Qin R, Mahal LK. Sweet systems: technologies for glycomic analysis and their integration into systems biology. Crit Rev Biochem Mol Biol 2021;56:301-20. [PMID: 33820453 DOI: 10.1080/10409238.2021.1908953] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Delgado JA, Ballesteros MA, Parera MM, Bauça JM. Pancreatic Cancer Insights: Optimization of the Diagnostic Capacity of Tumor Biomarkers. Lab Med 2021:lmab016. [PMID: 33900408 DOI: 10.1093/labmed/lmab016] [Reference Citation Analysis]
17 Lin KW, Ang TL, Li JW. Role of artificial intelligence in early detection and screening for pancreatic adenocarcinoma. Artif Intell Med Imaging 2022; 3(2): 21-32 [DOI: 10.35711/aimi.v3.i2.21] [Reference Citation Analysis]
18 Cui F, Zhou Z, Zhou HS. Review—Measurement and Analysis of Cancer Biomarkers Based on Electrochemical Biosensors. J Electrochem Soc 2020;167:037525. [DOI: 10.1149/2.0252003jes] [Cited by in Crossref: 39] [Cited by in F6Publishing: 2] [Article Influence: 19.5] [Reference Citation Analysis]
19 Guardado NV, Llorente K, Blondeau B. Evaluation and Management of Malignant Biliary Obstruction. Surg Oncol Clin N Am 2021;30:491-503. [PMID: 34053664 DOI: 10.1016/j.soc.2021.03.001] [Reference Citation Analysis]
20 Schizas D, Koumpoura A, Galari M, Economopoulou P, Vailas M, Sotiropoulou M, Dimitroulis D, Maroulis I, Felekouras E. A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. Per Med 2021;18:613-27. [PMID: 34676789 DOI: 10.2217/pme-2021-0031] [Reference Citation Analysis]
21 Gleeson FC. K-ras point mutation detection as an ancillary diagnostic biomarker: 1 step forward and 2 steps back? Gastrointest Endosc 2021;93:605-7. [PMID: 33583519 DOI: 10.1016/j.gie.2020.07.024] [Reference Citation Analysis]
22 El Aamri M, Yammouri G, Mohammadi H, Amine A, Korri-Youssoufi H. Electrochemical Biosensors for Detection of MicroRNA as a Cancer Biomarker: Pros and Cons. Biosensors (Basel) 2020;10:E186. [PMID: 33233700 DOI: 10.3390/bios10110186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Grzelak D. Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma. J Adv Pract Oncol 2021;12:488-91. [PMID: 34430059 DOI: 10.6004/jadpro.2021.12.5.4] [Reference Citation Analysis]
24 Turanli B, Yildirim E, Gulfidan G, Arga KY, Sinha R. Current State of "Omics" Biomarkers in Pancreatic Cancer. J Pers Med 2021;11:127. [PMID: 33672926 DOI: 10.3390/jpm11020127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Tavares Barroso M, Costa B, Rebelo de Almeida C, Castillo Martin M, Couto N, Carvalho T, Fior R. Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening. Cells 2021;10:2077. [PMID: 34440847 DOI: 10.3390/cells10082077] [Reference Citation Analysis]
26 Manne A, Esnakula A, Abushahin L, Tsung A. Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:3059. [PMID: 34205412 DOI: 10.3390/cancers13123059] [Reference Citation Analysis]
27 Al-Fatlawi A, Malekian N, García S, Henschel A, Kim I, Dahl A, Jahnke B, Bailey P, Bolz SN, Poetsch AR, Mahler S, Grützmann R, Pilarsky C, Schroeder M. Deep Learning Improves Pancreatic Cancer Diagnosis Using RNA-Based Variants. Cancers (Basel) 2021;13:2654. [PMID: 34071263 DOI: 10.3390/cancers13112654] [Reference Citation Analysis]
28 Del Vecchio Blanco G, Mossa M, Troncone E, Argirò R, Anderloni A, Repici A, Paoluzi OA, Monteleone G. Tips and tricks for the diagnosis and management of biliary stenosis-state of the art review. World J Gastrointest Endosc 2021; 13(10): 473-490 [PMID: 34733408 DOI: 10.4253/wjge.v13.i10.473] [Reference Citation Analysis]
29 Yang J, Xu R, Wang C, Qiu J, Ren B, You L. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun (Lond) 2021. [PMID: 34331845 DOI: 10.1002/cac2.12204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Nguyen HQ, Pham NTT, Hoang VT, Van HAT, Huynh C, Hoang DT. Diffuse Pancreatic Carcinoma with Hepatic Metastases. Case Rep Oncol Med 2020;2020:8815745. [PMID: 33194237 DOI: 10.1155/2020/8815745] [Reference Citation Analysis]
31 Gade A, Sharma A, Srivastava N, Flora SJS. Surface plasmon resonance: A promising approach for label-free early cancer diagnosis. Clin Chim Acta 2022:S0009-8981(22)00041-9. [PMID: 35120900 DOI: 10.1016/j.cca.2022.01.023] [Reference Citation Analysis]
32 Yu S, Wu Y, Li C, Qu Z, Lou G, Guo X, Ji J, Li N, Guo M, Zhang M, Lei L, Tai S. Comprehensive analysis of the SLC16A gene family in pancreatic cancer via integrated bioinformatics. Sci Rep 2020;10:7315. [PMID: 32355273 DOI: 10.1038/s41598-020-64356-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
33 Fu W, Wang K, Yan S, Wang X, Tang B, Chang J, Wang R, Wu T. Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis. Dose Response 2020;18:1559325820942065. [PMID: 32821253 DOI: 10.1177/1559325820942065] [Reference Citation Analysis]
34 Kane LE, Mellotte GS, Conlon KC, Ryan BM, Maher SG. Multi-Omic Biomarkers as Potential Tools for the Characterisation of Pancreatic Cystic Lesions and Cancer: Innovative Patient Data Integration. Cancers (Basel) 2021;13:769. [PMID: 33673153 DOI: 10.3390/cancers13040769] [Reference Citation Analysis]
35 Fiore M, Taralli S, Trecca P, Scolozzi V, Marinelli L, Triumbari EKA, Caputo D, Angeletti S, Ciccozzi M, Coppola A, Greco C, Ippolito E, Calcagni ML, Coppola R, Ramella S. A Bio-Imaging Signature as a Predictor of Clinical Outcomes in Locally Advanced Pancreatic Cancer. Cancers (Basel) 2020;12:E2016. [PMID: 32717967 DOI: 10.3390/cancers12082016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Duffy MJ, Diamandis EP, Crown J. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon? Clin Chem Lab Med 2021;59:1353-61. [PMID: 33856748 DOI: 10.1515/cclm-2021-0171] [Reference Citation Analysis]
37 Osei E, Oghinan C, Asare A, Ho H, Manful S. Review of clinical and emerging biomarkers for early diagnosis and treatment management of pancreatic cancer: towards personalised medicine. J Radiother Pract. [DOI: 10.1017/s1460396921000182] [Reference Citation Analysis]
38 Sebastian NT, Webb A, Merrell KW, Koay EJ, Wolfe AR, Zhang L, Wilhite TJ, Elganainy D, Robb R, Chen W, Cloyd J, Dillhoff M, Tsung A, Abushahin L, Noonan A, Williams TM. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:5168. [PMID: 34680317 DOI: 10.3390/cancers13205168] [Reference Citation Analysis]
39 Balouchi-Anaraki S, Ahmadvand S, Safaei A, Ghaderi A. 4H12, a Murine Monoclonal Antibody Directed against Myosin Heavy Chain-9 Expressed on Acinar Cell Carcinoma of Pancreas with Potential Therapeutic Application. Iran Biomed J 2021;25:310-22. [PMID: 34425650 DOI: 10.52547/ibj.25.5.310] [Reference Citation Analysis]
40 Lee MJ, Na K, Shin H, Kim CY, Cho JY, Kang CM, Kim SH, Kim H, Choi HJ, Lee CK, Bae S, Son S, Paik YK. Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role. J Proteome Res 2021;20:5315-28. [PMID: 34766501 DOI: 10.1021/acs.jproteome.1c00805] [Reference Citation Analysis]
41 Gardner KP, Aldakkak M, Tang CM, Tsai S, Adams DL. Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes. NPJ Precis Oncol 2021;5:25. [PMID: 33742084 DOI: 10.1038/s41698-021-00161-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Fathizadeh H, Hallajzadeh J, Asemi Z. Circular RNAs as diagnostic biomarker in pancreatic cancer. Pathology - Research and Practice 2020;216:153075. [DOI: 10.1016/j.prp.2020.153075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
43 Zong J, Fan Z, Zhang Y. Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:413-22. [PMID: 33376710 DOI: 10.2147/JHC.S272762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Fernandez Y Viesca M, Arvanitakis M. Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines. Clin Exp Gastroenterol. 2019;12:415-432. [PMID: 31807048 DOI: 10.2147/ceg.s195714] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
45 Lin WR, Yeh CT. GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers. Int J Mol Sci 2020;21:E1491. [PMID: 32098271 DOI: 10.3390/ijms21041491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Manoochehri M, Wu Y, Giese NA, Strobel O, Kutschmann S, Haller F, Hoheisel JD, Moskalev EA, Hackert T, Bauer AS. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis. Mol Oncol 2020;14:1252-67. [PMID: 32243066 DOI: 10.1002/1878-0261.12684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]